JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265979

Human OTUD4 (HIN-1) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

OTUD4 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 1 and Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human OTUD4 (HIN-1) knockout HeLa cell line (AB265979)
  • Sanger seq

Unknown

Sanger Sequencing - Human OTUD4 (HIN-1) knockout HeLa cell line (AB265979)

Allele-1 : 2 bp deletion in exon 1.

Sanger Sequencing - Human OTUD4 (HIN-1) knockout HeLa cell line (AB265979)
  • Sanger seq

Unknown

Sanger Sequencing - Human OTUD4 (HIN-1) knockout HeLa cell line (AB265979)

Allele-2 : Insertion of the selection cassette in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265979-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265979-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265979 Human OTUD4 (HIN-1) knockout HeLa cell line", "number":"AB265979-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265979-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265979-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265979 Human OTUD4 (HIN-1) knockout HeLa cell line", "number":"AB265979-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265979-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265979 Human OTUD4 (HIN-1) knockout HeLa cell line", "number":"AB265979-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265979-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265979 Human OTUD4 (HIN-1) knockout HeLa cell line", "number":"AB265979-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
OTUD4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

OTUD4/HIN-1 also known as ovarian tumor domain-containing protein 4 is known for its deubiquitinating enzyme activity. This protein shows a molecular mass of approximately 135 kDa. It is expressed in various tissues with significant levels observed in the brain and kidneys. OTUD4 plays a role in regulating protein degradation by removing ubiquitin impacting cellular processes such as protein turnover cell cycle regulation and signaling pathways.
Biological function summary

The OTUD4 protein significantly influences cellular homeostasis and stress response. It participates in the protein quality control system as part of a complex that regulates the ubiquitin-proteasome system. This protein ensures the proper folding and degradation of misfolded proteins impacting cellular health and function. OTUD4 forms interactions with other proteins highlighting its role in modulating cellular stress responses and apoptosis.

Pathways

OTUD4 has connections with both the ubiquitin-proteasome and DNA damage response pathways. It participates in the modulation of these pathways ensuring that damaged or misfolded proteins do not accumulate. OTUD4 directly interacts with proteins such as ubiquitin-specific proteases and E3 ligases influencing apoptosis and stress response. These interactions reveal its involvement in cellular decisions related to repair survival or apoptosis.

OTUD4 shows associations with neurodegenerative diseases and certain cancers. Dysregulation in its function can relate to protein aggregation in neurodegenerative conditions with its expression affecting pathways related to proteins like Parkin and UCH-L1. In cancers changes in OTUD4 expression can impact tumor growth and survival pointing towards its potential for therapeutic targeting and biomarker use in these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com